315 related articles for article (PubMed ID: 10660116)
1. Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4beta-amino-4'-O-demethylepipodophyllotoxin conjugates.
Chang JY; Guo X; Chen HX; Jiang Z; Fu Q; Wang HK; Bastow KF; Zhu XK; Guan J; Lee KH; Cheng YC
Biochem Pharmacol; 2000 Mar; 59(5):497-508. PubMed ID: 10660116
[TBL] [Abstract][Full Text] [Related]
2. Antitumor agents 294. Novel E-ring-modified camptothecin-4β-anilino-4'-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents.
Ye D; Shi Q; Leung CH; Kim SW; Park SY; Gullen EA; Jiang ZL; Zhu H; Morris-Natschke SL; Cheng YC; Lee KH
Bioorg Med Chem; 2012 Jul; 20(14):4489-94. PubMed ID: 22698783
[TBL] [Abstract][Full Text] [Related]
3. Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death.
Fu Q; Kim SW; Chen HX; Grill S; Cheng YC
Mol Pharmacol; 1999 Apr; 55(4):677-83. PubMed ID: 10101025
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
5. Effect of 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants.
Chang JY; Han FS; Liu SY; Wang ZQ; Lee KH; Cheng YC
Cancer Res; 1991 Apr; 51(7):1755-9. PubMed ID: 1848478
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
[TBL] [Abstract][Full Text] [Related]
7. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
8. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent.
Chang JY; Hsieh HP; Pan WY; Liou JP; Bey SJ; Chen LT; Liu JF; Song JS
Biochem Pharmacol; 2003 Jun; 65(12):2009-19. PubMed ID: 12787881
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
[TBL] [Abstract][Full Text] [Related]
11. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
Sorensen M; Sehested M; Christensen IJ; Larsen JK; Jensen PB
Br J Cancer; 1998 Jun; 77(12):2152-61. PubMed ID: 9649127
[TBL] [Abstract][Full Text] [Related]
12. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
13. Antitumor agents--CLXXIII. Synthesis and evaluation of camptothecin-4 beta-amino-4'-O-demethyl epipodophyllotoxin conjugates as inhibitors of mammalian DNA topoisomerases and as cytotoxic agents.
Bastow KF; Wang HK; Cheng YC; Lee KH
Bioorg Med Chem; 1997 Aug; 5(8):1481-8. PubMed ID: 9313854
[TBL] [Abstract][Full Text] [Related]
14. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines.
Beidler DR; Chang JY; Zhou BS; Cheng YC
Cancer Res; 1996 Jan; 56(2):345-53. PubMed ID: 8542590
[TBL] [Abstract][Full Text] [Related]
15. Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux.
Vanhuyse M; Kluza J; Tardy C; Otero G; Cuevas C; Bailly C; Lansiaux A
Cancer Lett; 2005 Apr; 221(2):165-75. PubMed ID: 15808402
[TBL] [Abstract][Full Text] [Related]
16. Antitumor agents. 234. Design, synthesis, and biological evaluation of novel 4beta-[(4' '-benzamido)-amino]-4'-o-demethyl-epipodophyllotoxin derivatives.
Xiao Z; Bastow KF; Vance JR; Sidwell RS; Wang HK; Chen MS; Shi Q; Lee KH
J Med Chem; 2004 Oct; 47(21):5140-8. PubMed ID: 15456257
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965
[TBL] [Abstract][Full Text] [Related]
18. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin).
Nagai S; Yamauchi M; Andoh T; Nishizawa M; Satta T; Kodera Y; Kondou K; Akiyama S; Ito K; Takagi H
J Surg Oncol; 1995 Jun; 59(2):116-24. PubMed ID: 7776652
[TBL] [Abstract][Full Text] [Related]
20. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity.
Beidler DR; Cheng YC
Mol Pharmacol; 1995 May; 47(5):907-14. PubMed ID: 7538195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
